Quest Diagnostics Inc last reported quarterly results on Oct 22, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $3.1 billion (+10.0% year over year) and diluted EPS of $2.78. It usually reports 12–23 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–23 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 22, 2026
22 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
3,097
+10.0%
|
312
+27.3%
|
2.78
+28.7%
|
|
Jul 23, 2026
23 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
3,043
+10.2%
|
320
+13.5%
|
2.84
+15.0%
|
|
Apr 21, 2026
21 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
2,895
+9.2%
|
252
+14.5%
|
2.24
+15.5%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
2,806
+7.1%
|
245
+10.4%
|
2.17
+13.3%
|
|
Oct 21, 2025
21 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
2,816
+13.2%
|
245
+8.4%
|
2.16
+8.5%
|
|
Jul 22, 2025
22 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
2,761
+15.2%
|
282
+23.1%
|
2.47
+21.7%
|
|
Apr 22, 2025
22 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2,652
+12.1%
|
220
+13.4%
|
1.94
+12.8%
|
|
Jan 30, 2025
30 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
2,621
+14.6%
|
222
+15.6%
|
1.91
+9.7%
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- DGX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Secaucus, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1022079
- Former names
- CORNING CLINICAL LABORATORIES INC (until Mar 19, 1997)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Source: SEC EDGAR filings. This is company-reported data, not investment advice.